Brief: Spruce Biosciences On March 16, Entered Termination Agreement With Kaken Pharmaceutical - SEC Filing
20/03/2026 21:42
March 20 (Reuters) - SEC Filing: SPRUCE BIOSCIENCES INC - ON MARCH 16, ENTERED TERMINATION AGREEMENT WITH KAKEN PHARMACEUTICAL - SEC FILING SPRUCE BIOSCIENCES INC - COLLABORATION AGREEMENT WITH KAKEN PHARMACEUTICAL TO TERMINATE EFFECTIVE MARCH 31, 2026 - SEC FILING SPRUCE BIOSCIENCES INC - ALL LICENSES & RIGHTS GRANTED BY CO TO KAKEN TO BE TERMINATDE; NO UNEARNED MILESTONE PAYMENTS OR ROYALTIES Source text: [ID:n0001193125-26-117888] Further company coverage: SPRB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium